Recombinant expression of PCV2b ORF2 protein in insect cells
The present invention relates to the field of veterinary vaccines, in particular to porcine vaccines against PCV2 and associated diseases. Specifically the invention relates to the finding that a mutation is required in PCV2b ORF2 protein, to prevent its nuclear accumulation upon expression in insect cells; the mutation introduces a Proline at amino acid position 131. This allows efficient expression in insect cells, easy harvesting, and generates large amounts of virus-like particles. The VLPs are highly effective in vaccines for porcines for reduction of infection by PCV2 or of associated signs of disease.
1. An insect cell comprising a heterologous nucleic acid comprising:
a. a nucleotide sequence encoding an ORF2 protein from porcine circovirus 2 of genotype 2b (PCV2b), and
b. a transcription control sequence that is operatively linked to said nucleotide sequence, wherein the nucleotide sequence encodes a mutant PCV2b ORF2 protein having a Proline at amino acid position number 131.
2. The insect cell of claim 1 , wherein the transcription control sequence is selected from the group consisting of a baculovirus p10 gene promoter and a baculovirus polyhedrin gene promoter.
3. The insect cell of claim 1 , wherein the heterologous nucleic acid is comprised in a recombinant baculovirus genome.
4. A method of producing a mutant PCV2b ORF2 protein having a Proline at amino acid position number 131, comprising culturing the insect cell of claim 1 ; wherein the mutant PCV2b ORF2 protein is produced; and whereby an insect cell culture is formed.
5. The method of claim 4 , further comprising harvesting the mutant PCV2b ORF2 protein from the insect cell culture.
6. The method of claim 5 , wherein said insect cell is a baculovirus-insect cell.
7. The method of claim 4 , wherein said insect cell is a baculovirus-insect cell.
8. A virus-like particle (VLP) of a mutant PCV2b ORF2 protein, wherein the mutant PCV2b ORF2 protein has a Proline at amino acid position number 131.
9. A vaccine for porcine animals for reducing infection by PCV2 or reducing associated signs of disease, comprising a mutant PCV2b ORF2 protein in a pharmaceutically acceptable carrier and an adjuvant, wherein the mutant PCV2b ORF2 protein has a Proline at amino acid position number 131.
10. The vaccine of claim 9 , wherein the mutant PCV2b ORF2 protein is in the form of a virus-like particle.
11. The vaccine of claim 9 , further comprising an antigen from a micro-organism that is pathogenic to porcine animals.
12. A method of reducing an infection by PCV2 or reducing associated signs of disease in a porcine animal, comprising administering to said porcine animal the vaccine of claim 9 .
13. A process of preparing a vaccine of claim 9 , comprising admixing a mutant PCV2b ORF2 protein having a Proline at amino acid position number 131, with a pharmaceutically acceptable carrier and an adjuvant, thereby forming an admixture.